324 related articles for article (PubMed ID: 37519261)
1. Use of Saccharomyces boulardii CNCM I-745 as therapeutic strategy for prevention of nonsteroidal anti-inflammatory drug-induced intestinal injury.
D'Antongiovanni V; Antonioli L; Benvenuti L; Pellegrini C; Di Salvo C; Calvigioni M; Panattoni A; Ryskalin L; Natale G; Banni S; Carta G; Ghelardi E; Fornai M
Br J Pharmacol; 2023 Dec; 180(24):3215-3233. PubMed ID: 37519261
[TBL] [Abstract][Full Text] [Related]
2. Protective effects of the combination Bifidobacterium longum plus lactoferrin against NSAID-induced enteropathy.
Fornai M; Pellegrini C; Benvenuti L; Tirotta E; Gentile D; Natale G; Ryskalin L; Colucci R; Piccoli E; Ghelardi E; Blandizzi C; Antonioli L
Nutrition; 2020 Feb; 70():110583. PubMed ID: 31739175
[TBL] [Abstract][Full Text] [Related]
3. Protective effects of Saccharomyces boulardii CNCM I-745 in an experimental model of NSAID-induced enteropathy.
Simon O'Brien E; Robert A; Gauthier D; Le Cavorzin A; Planchais J; Roux X; Verleye M; Castagné V
Benef Microbes; 2023 Sep; 14(3):239-253. PubMed ID: 37646075
[TBL] [Abstract][Full Text] [Related]
4. Modulation of 5-fluorouracil activation of toll-like/MyD88/NF-κB/MAPK pathway by Saccharomyces boulardii CNCM I-745 probiotic.
Justino PFC; Franco AX; Pontier-Bres R; Monteiro CES; Barbosa ALR; Souza MHLP; Czerucka D; Soares PMG
Cytokine; 2020 Jan; 125():154791. PubMed ID: 31401369
[TBL] [Abstract][Full Text] [Related]
5. Pathophysiology of NSAID-Associated Intestinal Lesions in the Rat: Luminal Bacteria and Mucosal Inflammation as Targets for Prevention.
Colucci R; Pellegrini C; Fornai M; Tirotta E; Antonioli L; Renzulli C; Ghelardi E; Piccoli E; Gentile D; Benvenuti L; Natale G; Fulceri F; Palazón-Riquelme P; López-Castejón G; Blandizzi C; Scarpignato C
Front Pharmacol; 2018; 9():1340. PubMed ID: 30555323
[TBL] [Abstract][Full Text] [Related]
6. Saccharomyces boulardii CNCM I-745 supplementation reduces gastrointestinal dysfunction in an animal model of IBS.
Brun P; Scarpa M; Marchiori C; Sarasin G; Caputi V; Porzionato A; Giron MC; Palù G; Castagliuolo I
PLoS One; 2017; 12(7):e0181863. PubMed ID: 28732069
[TBL] [Abstract][Full Text] [Related]
7.
Gao H; Li Y; Sun J; Xu H; Wang M; Zuo X; Fu Q; Guo Y; Chen Z; Zhang P; Li X; Wang N; Ye T; Yao Y
Oxid Med Cell Longev; 2021; 2021():1622375. PubMed ID: 34367460
[No Abstract] [Full Text] [Related]
8. Diversity of
Czerucka D; Rampal P
World J Gastroenterol; 2019 May; 25(18):2188-2203. PubMed ID: 31143070
[TBL] [Abstract][Full Text] [Related]
9. [Saccharomyces boulardii CNCM I-745 - the medicinal yeast improves intestinal enzyme function].
Moré MI
MMW Fortschr Med; 2019 Mar; 161(Suppl 4):20-24. PubMed ID: 30895510
[TBL] [Abstract][Full Text] [Related]
10.
Briand F; Sulpice T; Giammarinaro P; Roux X
Benef Microbes; 2019 May; 10(5):555-567. PubMed ID: 31090460
[TBL] [Abstract][Full Text] [Related]
11. Protective effect and mechanism of rebamipide on NSAIDs associated small bowel injury.
Xu N; Zhang C; Jing L; Mou S; Cao X; Yu Z
Int Immunopharmacol; 2021 Jan; 90():107136. PubMed ID: 33218942
[TBL] [Abstract][Full Text] [Related]
12. Role of proteinase-activated receptors 1 and 2 in nonsteroidal anti-inflammatory drug enteropathy.
Fornai M; Colucci R; Pellegrini C; Benvenuti L; Natale G; Ryskalin L; Blandizzi C; Antonioli L
Pharmacol Rep; 2020 Oct; 72(5):1347-1357. PubMed ID: 32583327
[TBL] [Abstract][Full Text] [Related]
13. Effect of Saccharomyces boulardii CNCM I-745 as complementary treatment of Helicobacter pylori infection on gut microbiome.
Cárdenas PA; Garcés D; Prado-Vivar B; Flores N; Fornasini M; Cohen H; Salvador I; Cargua O; Baldeón ME
Eur J Clin Microbiol Infect Dis; 2020 Jul; 39(7):1365-1372. PubMed ID: 32125555
[TBL] [Abstract][Full Text] [Related]
14. Saccharomyces boulardii ameliorates clarithromycin- and methotrexate-induced intestinal and hepatic injury in rats.
Duman DG; Kumral ZN; Ercan F; Deniz M; Can G; Cağlayan Yeğen B
Br J Nutr; 2013 Aug; 110(3):493-9. PubMed ID: 23279717
[TBL] [Abstract][Full Text] [Related]
15. Saccharomyces boulardii CNCM I-745: A Non-bacterial Microorganism Used as Probiotic Agent in Supporting Treatment of Selected Diseases.
Kaźmierczak-Siedlecka K; Ruszkowski J; Fic M; Folwarski M; Makarewicz W
Curr Microbiol; 2020 Sep; 77(9):1987-1996. PubMed ID: 32472262
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of
Maev IV; Andreev DN; Sokolov PS; Fomenko AК; Devkota MK; Andreev NG; Zaborovsky AV
Ter Arkh; 2022 Nov; 94(10):1163-1170. PubMed ID: 36468990
[TBL] [Abstract][Full Text] [Related]
17. [Protective effect of Saccharomyces boulardii against intestinal mucosal barrier injury in rats with nonalcoholic fatty liver disease].
Liu YT; Li YQ; Wang YZ
Zhonghua Gan Zang Bing Za Zhi; 2016 Dec; 24(12):921-926. PubMed ID: 28073414
[No Abstract] [Full Text] [Related]
18. [Effect of muscovite on non-steroidal anti-inflammatory drug associated intestinal injury and its influences on tumor necrosis factor-alpha and nuclear factor-kappaB in rats].
Meng LN; Fang L; Lu B
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2010 Sep; 30(9):961-5. PubMed ID: 21179738
[TBL] [Abstract][Full Text] [Related]
19. Prospective randomized controlled study on the effects of Saccharomyces boulardii CNCM I-745 and amoxicillin-clavulanate or the combination on the gut microbiota of healthy volunteers.
Kabbani TA; Pallav K; Dowd SE; Villafuerte-Galvez J; Vanga RR; Castillo NE; Hansen J; Dennis M; Leffler DA; Kelly CP
Gut Microbes; 2017 Jan; 8(1):17-32. PubMed ID: 27973989
[TBL] [Abstract][Full Text] [Related]
20. Ciprofloxacin blocked enterohepatic circulation of diclofenac and alleviated NSAID-induced enteropathy in rats partly by inhibiting intestinal β-glucuronidase activity.
Zhong ZY; Sun BB; Shu N; Xie QS; Tang XG; Ling ZL; Wang F; Zhao KJ; Xu P; Zhang M; Li Y; Chen Y; Liu L; Xia LZ; Liu XD
Acta Pharmacol Sin; 2016 Jul; 37(7):1002-12. PubMed ID: 27180979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
